- Home
- CVAC vs ARDX Comparison
CVAC vs ARDX Comparison
Compare CVAC & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- ARDX
- Stock Information
- Founded
- CVAC 2000
- ARDX 2007
- Country
- CVAC Germany
- ARDX United States
- Employees
- CVAC N/A
- ARDX N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- CVAC Health Care
- ARDX Health Care
- Exchange
- CVAC Nasdaq
- ARDX Nasdaq
- Market Cap
- CVAC 764.4M
- ARDX 885.2M
- IPO Year
- CVAC 2020
- ARDX 2014
- Fundamental
- Price
- CVAC $5.40
- ARDX $4.19
- Analyst Decision
- CVAC Hold
- ARDX Strong Buy
- Analyst Count
- CVAC 3
- ARDX 9
- Target Price
- CVAC $6.83
- ARDX $10.17
- AVG Volume (30 Days)
- CVAC 2.1M
- ARDX 4.7M
- Earning Date
- CVAC 08-14-2025
- ARDX 07-31-2025
- Dividend Yield
- CVAC N/A
- ARDX N/A
- EPS Growth
- CVAC N/A
- ARDX N/A
- EPS
- CVAC 0.87
- ARDX N/A
- Revenue
- CVAC $566,039,775.00
- ARDX $361,706,000.00
- Revenue This Year
- CVAC N/A
- ARDX $12.01
- Revenue Next Year
- CVAC $24.04
- ARDX $34.66
- P/E Ratio
- CVAC $6.22
- ARDX N/A
- Revenue Growth
- CVAC 787.60
- ARDX 127.33
- 52 Week Low
- CVAC $2.37
- ARDX $3.21
- 52 Week High
- CVAC $5.72
- ARDX $7.18
- Technical
- Relative Strength Index (RSI)
- CVAC 64.78
- ARDX 63.34
- Support Level
- CVAC $5.33
- ARDX $3.49
- Resistance Level
- CVAC $5.58
- ARDX $3.72
- Average True Range (ATR)
- CVAC 0.12
- ARDX 0.18
- MACD
- CVAC -0.04
- ARDX 0.07
- Stochastic Oscillator
- CVAC 23.81
- ARDX 82.36
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.